Unlock all Features See Plans and Pricing

Serving leading biopharmaceutical companies globally:

Harvard Business School
Express Scripts

Last Updated: September 26, 2022

Details for Patent: 9,345,750

✉ Email this page to a colleague

« Back to Dashboard

▶ Start for $1
Remove trial restrictions

Summary for Patent: 9,345,750
Title:Long-acting formulations of insulin
Abstract: The application relates to an aqueous pharmaceutical formulation comprising 200-1000 U/mL [equimolar to 200-1000 IU human insulin] of insulin glargine.
Inventor(s): Becker; Reinhard (Frankfurt am Main, DE), Hahn; Annke (Frankfurt am Main, DE), Boderke; Peter (Schwalbach, DE), Fuerst; Christiane (Frankfurt am Main, DE), Mueller; Werner (Frankfurt am Main, DE), Werner; Ulrich (Frankfurt am Main, DE)
Assignee: SANOFI (Paris, FR)
Application Number:14/220,562
Patent Claim Types:
see list of patent claims
Formulation; Composition; Use;

Drugs Protected by US Patent 9,345,750

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

Foreign Priority and PCT Information for Patent: 9,345,750

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
10305532May 19, 2010
10305780Jul 13, 2010
11305140Feb 10, 2011

International Family Members for US Patent 9,345,750

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Argentina 081200 See Plans and Pricing
Australia 2011202239 See Plans and Pricing
Australia 2012216648 See Plans and Pricing
Australia 2014203421 See Plans and Pricing
Brazil 112012029131 See Plans and Pricing
Canada 2792669 See Plans and Pricing
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Harvard Business School
Boehringer Ingelheim

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.